Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Details) - Schedule of stock options outstanding and exercisable

v3.21.1
Stockholders' Equity (Details) - Schedule of stock options outstanding and exercisable
 3 Months Ended
Mar. 31, 2021
$ / shares
shares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Stock Options, Weighted Average Exercise Price
Stock Options, Total Outstanding (in Shares) (in Shares) | shares 6,805,538
Stock Options, Number Exercisable (in Shares) (in Shares) | shares 4,923,099
Grant Price From 0.26 To 2.02 [Member]  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Stock Options, Grant Price, Minimum $ 0.26
Stock Options, Weighted Average Exercise Price $ 0.71
Stock Options, Total Outstanding (in Shares) (in Shares) | shares 2,455,621
Stock Options, Number Exercisable (in Shares) (in Shares) | shares 2,286,454
Stock Options, Weighted Average Remaining Contractual Term 4 years 43 days
Stock Options, Grant Price, Maximum $ 2.02
Grant Price From 2.10 To 4.60 [Member]  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Stock Options, Grant Price, Minimum 2.10
Stock Options, Weighted Average Exercise Price $ 2.42
Stock Options, Total Outstanding (in Shares) (in Shares) | shares 3,756,917
Stock Options, Number Exercisable (in Shares) (in Shares) | shares 2,084,249
Stock Options, Weighted Average Remaining Contractual Term 7 years 186 days
Stock Options, Grant Price, Maximum $ 4.60
Grant Price From 5.30 To 8.86 [Member]  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Stock Options, Grant Price, Minimum 5.30
Stock Options, Weighted Average Exercise Price $ 6.25
Stock Options, Total Outstanding (in Shares) (in Shares) | shares 593,000
Stock Options, Number Exercisable (in Shares) (in Shares) | shares 552,396
Stock Options, Weighted Average Remaining Contractual Term 7 years 32 days
Stock Options, Grant Price, Maximum $ 8.86